This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and/or duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 18 to 65 years
* Diagnosis of fibromyalgia syndrome according to the 2016 ACR criteria
* Followed in a physical medicine and rehabilitation outpatient clinic for at least 1 year
* Receiving pregabalin and/or duloxetine treatment for at least 3 months
* Able to live independently in the community
* Literate and able to record symptoms and responses
* No cognitive dysfunction that would interfere with answering study questions
* Able and willing to provide informed consent
Exclusion Criteria:
* Rheumatologic disease
* Renal failure
* Hepatic failure
* Cardiovascular disease
* Hypoglycemia or diabetes mellitus
* Any neurologic disease (such as stroke, spinal cord injury, multiple sclerosis, or Parkinson's disease)
* Known allergy or hypersensitivity to any active or excipient component of the study syrup
* Use of any other dietary supplement or nutritional support product during the study period
* Pregnancy or lactation
* Active malignancy
* Active infection
* Severe psychiatric disease that may interfere with study participation or assessment
* Refusal to participate or inability to provide informed consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Pain Intensity Measured by Numeric Rating Scale (NRS)
Timeframe: Baseline, Week 2, and Week 4
Trial details
NCT IDNCT07495943
SponsorHaydarpasa Numune Training and Research Hospital